Rapamycin (Sirolimus)

For research use only.

Licensed by Pfizer Catalog No.S1039 Synonyms: AY 22989，NSC-2260804

1158 publications

Rapamycin (Sirolimus) Chemical Structure

CAS No. 53123-88-9

Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.

Size Price Stock Quantity  
10mM (1mL in DMSO) USD 306 In stock
USD 70 In stock
USD 270 In stock
USD 670 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's Rapamycin (Sirolimus) has been cited by 1158 publications

Purity & Quality Control

Choose Selective mTOR Inhibitors

Biological Activity

Description Rapamycin (Sirolimus, AY 22989, NSC-2260804) is a specific mTOR inhibitor with IC50 of ~0.1 nM HEK293 cells.
Targets
mTOR [1]
(HEK293 cells)
~0.1 nM
In vitro

Rapamycin inhibits endogenous mTOR activity in HEK293 cells with IC50 of ~0.1 nM, more potently than iRap and AP21967 with IC50 of ~5 nM and ~10 nM, respectively. [1] In Saccharomyces cerevisiae, Rapamycin treatment induces a severe G1/S cell cycle arrest and inhibition of translation initiation to levels below 20% of control. [2] Rapamycin significantly inhibits the cell viability of T98G and U87-MG in a dose-dependent manner with IC50 of 2 nM and 1 μM, respectively, while displaying little activity against U373-MG cells with IC50 of >25 μM despite the similar extent of the inhibition of mTOR signaling. Rapamycin (100 nM) induces G1 arrest and autophagy but not apoptosis in Rapamycin-sensitive U87-MG and T98G cells by inhibiting the function of mTOR. [3]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HT-29 NGK1WJhEgXSxdH;4bYMhSXO|YYm= NHP4bGUyOCCwTR?= NUmwVXNuPzJiaB?= MV7EUXNQ MkLpVI91\W62aXH0[ZMh[2GvcITveIhm[2mwLXnu[JVk\WRiY4n0c5RwgGmlaYT5 NF7aPHUzPDlyMEi3Ny=>
HT-29 NHHLWpFEgXSxdH;4bYMhSXO|YYm= MnjLNVAhdk1? M2fiXlczKGh? MnHsSG1UVw>? NIiwSVFRd3SnboTpZZRmeyCmaXfpeI95cW5vaX7keYNm\CCleYTveI95cWOrdIm= NXLSNVltOjR7MEC4O|M>
HT-29 NI\VRZpEgXSxdH;4bYMhSXO|YYm= NGjrfGYyOCCwTR?= MnHmO|IhcA>? NEX5bXFFVVOR M3zJRnBwfGWwdHnheIV{KDVvZnz1c5JwfXKjY3nsMYlv\HWlZXSgZ5l1d3SxeHnjbZR6 M3GwbFI1QTByOEez
PC3 NWfI[ndmU2mwYYPlJGF{e2G7 MmewNVAxKG6P MlH0NUBp Moi4SG1UVw>? MUnQc5RmdnSueTDpcohq[mm2czDtWG9TNW2nZHnheIVlKFN4IIDoc5NxcG:{eXzheIlwdiC5aYToJGlEPTBib3[gQFExKG6PLh?= NUHSZXlsOjF7N{i2PFM>
PC3 MUXLbY5ie2ViQYPzZZk> NYj2ZpkxOTByIH7N NUf2U|NMOSCq M3nafWROW09? MlnOSI9meyCwb4SgbY5pcWKrdDDtWG9TNW2nZHnheIVlKEGtdDDwbI9{eGixconsZZRqd25? MnrHNlE6Pzh4OEO=
PC3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmj3NU42KM7:TR?= NXGyWFVJOSCq M{exdmROW09? NXvh[XFmUW6mdXPld{BidnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhRDFyIH7N NFyxWnQzOTl5OE[4Ny=>
HEK293 MXjGeY5kfGmxbjDBd5NigQ>? NYW0NnFiOTByIH7N NWC4TW02QCCq NYjFXmxETE2VTx?= MYPJcohq[mm2czDUVGEucW6mdXPl[EBl\We{YXTheIlwdiCxZjDQ[INlPCC5aYToJGVEPTBib3[gOVAhdk1? NEXCXGIzOTV|OUOwNS=>
BT-20 NFPnRldMcW6jc3WgRZN{[Xl? MX6yNEDPxE1? MoLuSG1UVw>? MoGzSI9meyCwb4SgbY5pcWKrdDDtWG9TSzJiZHXw[Y5l\W62IIDBb3QhWzR5MzDwbI9{eGixconsZZRqd25? MlHxNlE{PTN3NUG=
U937 MWPBcpRq[mGldHXybYFtKEG|c3H5 MVG1NEDPxE1? MW[0PEBp M13jSmROW09? NW\4eo5rUW6mdXPld{BidnSrYnHjeIVzcWGuIHHjeIl3cXS7IHHnZYlve3Rid3ns[EB1gXCnIFzl[4lwdmWubHGgdI5mfW2xcHjpcIEhWGirbHHk[YxxcGmjLUGgTnI{OiCrbjDVPVM4KGOnbHzz NFPCWYUzOTF2MkGwOi=>
U937 NUfVc25vSW62aXLhZ5RmemmjbDDBd5NigQ>? MVi1NEDPxE1? M171N|Q5KGh? NFjNb4dFVVOR MXHEc4V{KG6xdDDpcoR2[2ViYX70bYJi[3SncnnhcEBi[3Srdnn0fUBi\2GrboP0JG1KWCCycn;0[YlvNWSnZnnjbYVvfCCOZXfpc45mdGyjIIDu[ZVud3CqaXzhJGpTOzJvMjDpckBWQTN5IHPlcIx{ MVmyNVE1OjFyNh?=
U937 NGK2OHVCdnSrYnHjeIVzcWGuIFHzd4F6 MkX1OVAh|ryP Mmq3OFghcA>? NIjOTIpFVVOR M{Ltd2Rw\XNibn;0JIlv\HWlZTDhcpRq[mGldHXybYFtKGGldHn2bZR6KGGpYXnud5QhTXOlaHXybYNpcWFiY3;sbUBJSjFyMTDpckBWQTN5IHPlcIx{ NYO3WYRROjFzNEKxNFY>
MCF-7 NVnpWWZlSXW2b4DoZYd6KEG|c3H5 NGKyO2o{OCCwTR?= MXe0JIg> M{ToW2ROW09? NIfJOpdKdmS3Y3XzJIF2fG:yaHHnfS=> MX[yNFAzQDF|NB?=
U87MG MUjLbY5ie2ViQYPzZZk> MkfWNUDPxE1? Ml;MOkBp NWSwWJZwTE2VTx?= MoDVVI91\W62bImgbY5pcWKrdIOgcXRQWi2vZXTpZZRm\CCVNjDwbI9{eGixconsZZRqd25? NH;neWYyQTh2OESwOC=>
U87MG Mlz3T4lv[XOnIFHzd4F6 MoXLNUDPxE1? NXXtSJl[PiCq M170O2ROW09? MlfFVI91\W62bImgbY5pcWKrdIOgOGVDWDFqVEewLUBxcG:|cHjvdplt[XSrb36= M4my[|E6QDR6NEC0
U87MG NHnsTIRMcW6jc3WgRZN{[Xl? NIS1N3gyKM7:TR?= MYG2JIg> Ml24SG1UVw>? NH\XS3pFd2W|IH7veEBqdmirYnn0JI1VV1JvbXXkbYF1\WRiQXv0JJBpd3OyaH;yfYxifGmxbh?= MkjONVk5PDh2MES=
U87MG NVThXlBiU2mwYYPlJGF{e2G7 M132VVEh|ryP MVe2JIg> NELZVFJFVVOR NW\BOZlWTG:nczDuc5QhcW6qaXLpeEBRNTSHQmCxLHQ{Py92NjmgdIhwe3Cqb4L5cIF1cW:w NFT6NYMyQTh2OESwOC=>
COS7 cells expressing EGFP-HDQ74/rheb MVfBeZRweGijZ4mgRZN{[Xl? MojnNE4zKM7:TR?= NIX2XGozPCCq MXPEUXNQ MkLYTY5lfWOnczDheZRweGijZ4m= M1TQT|E5OzlzOUS5
COS7 cells expressing EGFP-LC3 NVf3fHRISXW2b4DoZYd6KEG|c3H5 MYSwMlIh|ryP MmTYNlQhcA>? MonLSG1UVw>? MYDJcoR2[2W|IHH1eI9xcGGpeR?= MXixPFM6OTl2OR?=
H4 M3XjcWZ2dmO2aX;uJGF{e2G7 NUnBcGRqOC5{IN88US=> NXuwTlJEOjRiaB?= MVHEUXNQ MYPJcoNz\WG|ZYOgeIhmKHKjdHnvJI9nKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCyJJRwKGyrZ3j0JINp[WmwIEOgd5VjfW6rdDCxJIlvKGi3bXHuJGg1KGOnbHzz MUGxPFAzPDV6NB?=
HeLa MkTHSpVv[3Srb36gRZN{[Xl? NGOw[I4yODBibl2= M17kZVM3KGh? NYHCV2tYTE2VTx?= M2jxfWlv\HWlZYOgSnJDKEt{MEm1VEwhXDJyOUjMMEBYOjFyMV[gcZV1[W62LYXibZF2cXSrblOgbY51\XKjY4Tpc44> NF7r[GgyPzV4M{O4OS=>
HeLa M{j0S2Z2dmO2aX;uJGF{e2G7 MmD4NVAxKG6P MXezOkBp MX3EUXNQ MmfFTY5lfWOnczDGVmIhXzJzMEHGJI12fGGwdD31ZolyfWm2aX7DJIlvfGW{YXP0bY9v MnziNVc2PjN|OEW=
HeLa MnvJSpVv[3Srb36gRZN{[Xl? NFLqZoIyODBibl2= MXyzOkBp NFzhSGtFVVOR NVixNJZNUW6mdXPld{BHWkJvRlvCVEBkd22ybHX4JIlvfGW{YXP0bY9v MnPiNVc2PjN|OEW=
SYF NWDBdnVWTnWwY4Tpc44hSXO|YYm= NWfLPGJlOTByIH7N MlfiNlQhcA>? M2TOT2ROW09? Mlr0TY5lfWOnczDGVmIuTkuEUDDjc41xdGW6IHnueIVz[WO2aX;u NUHCNGk5OTd3NkOzPFU>
SYF NWL5e3dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX6xNFAhdk1? MmfINlQhcA>? Mn\uSG1UVw>? NIXWe5BKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgV3lHKGOnbHzz Mn3BNVc2PjN|OEW=
HEK293T MljGRY51cX[rcnHsJGF{e2G7 NVTZe29KOSCwTR?= NXzKXGpRPCCm MVrEUXNQ NFHxdHNKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiUkWge4l1cCCHQ{WwJI9nKDBwMTDuUS=> M1nMR|E4PDh3NUCx
HEK293T NV;WPG5CSW62aY\pdoFtKEG|c3H5 Mn\0NUBvVQ>? M3;wfFQh\A>? MV;EUXNQ NEnkXphKdmS3Y3XzJIFvfGm4aYLhcEBi[3Srdnn0fUBi\2GrboP0JGhKXjFiWESge4l1cCCHQ{WwJI9nKDBwMzDuUS=> M2fGdFE4PDh3NUCx
PBMC MlTxSpVv[3Srb36gRZN{[Xl? NI\HR2IyKG6P MkjyNVQh\A>? M1jjNGROW09? MX;S[YR2[2W|IFPDVlUh\GWwc3n0fS=> MVWxO|Q5PTVyMR?=
PBMC M4\S[WZ2dmO2aX;uJGF{e2G7 NIfEU5gyKG6P NWDEdnE4OTRiZB?= MoTESG1UVw>? NF3Qbm1Fd2W|IH7veEBi\m[nY4SgR3hEWjRiZHXud4l1gQ>? MVWxO|Q5PTVyMR?=
HEK293 cells MVHLbY5ie2ViQYPzZZk> MkDwOVAhdk1? NUXwWlR1PDVibXnu NF\FVWZFVVOR MW\Jcohq[mm2czDtWG9TKGurbnHz[UBi[3Srdnn0fUB4cXSqIFnDOVAhd2ZiMD6xJI5O NVKyXWpnOTd|NUC5OVM>
Drosophila melanogaster S2 cells transfected with N-luc and C-luc M1vwNmZ2dmO2aX;uJGF{e2G7 M1TlRlExOCCwTR?= NGHTSos1KGh? MWHEUXNQ Mo\lTY5lfWOnczDseYNq\mW{YYPlJJBzd3SnaX6geJJidnNvc4DsbYNqdmdiaX6gSJJwe2:yaHnsZUBu\Wyjbn;nZZN1\XJiU{KgZ4VtdHNidILhcpNn\WO2ZXSge4l1cCCQLXz1Z{BidmRiQz3seYM> M1n1eVE4OTJ6Mk[y
Human mixed lymphocyte M3W1O2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1yycVUhdk1? M1OyfWROW09? M2rHeWlEPTB;MT62JI5ONg>? MXmxOlE5PTh4NR?=
Lewis rat lymph node cells NHTyWm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELudGE2KM7:TR?= NYGwTYk2TE2VTx?= M1rqN2lEPTB;Mj62JO69VQ>? MY[xOlE5PTh4NR?=
cells from the thymus of normal BALB/c mice NFvXe5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorXNVAhdk1? MUG3NkBp NEO4TnlFVVOR NX35[Xh[UW6qaXLpeJMhdHmvcHjvdJJwdGmoZYLheIlwdiBqTFHGLUB4cXSqIFnDOVAhd2ZiMzDuUS=> NIDmc4syODB{MUm0PC=>
MRK-nu-1 M1;UZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXC[odKSzVyPUCuPFQ2KHCP NVToPGx5W0GQR1XS
OCUB-M MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWPJR|UxRTVwMkSgdG0> NH;GeGtUSU6JRWK=
SF539 MljRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHXQWnVKSzVyPUGxMlYheE1? MVHTRW5ITVJ?
ES4 Mlu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJzLkWgdG0> M2rIenNCVkeHUh?=
RL95-2 NX3rPZJRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HvOmlEPTB;MUC3JJBO Mn\OV2FPT0WU
LC-2-ad NVPjdFNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoPRTWM2OD12MkOgdG0> MVrTRW5ITVJ?
Daudi NUTLbnA6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL4eIhKSzVyPUSzOEBxVQ>? MX;TRW5ITVJ?
NTERA-S-cl-D1 NGXCOZlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXQNJE6UUN3ME20OFMheE1? NH[zWXNUSU6JRWK=
OS-RC-2 MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTZ3MjDwUS=> MmD2V2FPT0WU
VA-ES-BJ M4HYRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\XeWlEPTB;N{KzJJBO MUfTRW5ITVJ?
GR-ST MnHyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTh2NjDwUS=> M1KyfXNCVkeHUh?=
SW872 Mm[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL1VIhKSzVyPUi0OkBxVQ>? MWnTRW5ITVJ?
NOS-1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTh5MTDwUS=> MnTxV2FPT0WU
MC116 NV\pNm5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfPe4NKSzVyPUm4OUBxVQ>? MWnTRW5ITVJ?
NCI-H1355 M2PEW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjhSYpKSzVyPUGuNFEhdk1? M{nqUHNCVkeHUh?=
RPMI-8226 NF\afopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\4NVVmUUN3ME2xMlE6KG6P M2m4ZXNCVkeHUh?=
TE-15 NFXEb4JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX0U2lTUUN3ME2xMlM3KG6P MV7TRW5ITVJ?
Ramos-2G6-4C10 M3TWWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnRfWVKSzVyPUGuOFYhdk1? MV;TRW5ITVJ?
KU812 MnvlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLCTWM2OD1{LkCxJI5O MV;TRW5ITVJ?
EW-1 NFi0T3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHMbWdKSzVyPUKuNVchdk1? M{[zSXNCVkeHUh?=
KS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJwNEWgcm0> NXj0VXFzW0GQR1XS
SK-LMS-1 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLlc2xKSzVyPUKuOFkhdk1? MmnQV2FPT0WU
TGBC1TKB NU[0PHdwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTJwNkmgcm0> NEDpW|dUSU6JRWK=
TE-6 NV6wV3g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDaTWM2OD1{Lke3JI5O NGfhWIhUSU6JRWK=
ETK-1 NWmxc4E2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnqe2x2UUN3ME2yMlgzKG6P M4PaU3NCVkeHUh?=
BE-13 MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTJwOUmgcm0> MnnHV2FPT0WU
A3-KAW MmKzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPre4h1UUN3ME2yMlk6KG6P M1:ybnNCVkeHUh?=
TE-10 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTNwMzDuUS=> NUO3c5ZLW0GQR1XS
DOHH-2 MmDWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTNwM{Wgcm0> M3izTnNCVkeHUh?=
ES6 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVm3ZnFnUUN3ME2zMlQ{KG6P NF2yNYdUSU6JRWK=
OPM-2 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;VTWM2OD12LkG1JI5O MUfTRW5ITVJ?
SH-4 NX3rTIdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\3TVBnUUN3ME20MlM1KG6P MonYV2FPT0WU
NB13 NWHhfm5vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTRwM{[gcm0> NIe4U2pUSU6JRWK=
HUTU-80 NUTWb41XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWTJR|UxRTRwNEKgcm0> MXXTRW5ITVJ?
CCRF-CEM MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{flWGlEPTB;ND65OEBvVQ>? NWO2fmU1W0GQR1XS
TGBC24TKB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\H[mlEPTB;NT61NUBvVQ>? MlnpV2FPT0WU
697 M1PVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTZwMkigcm0> Ml;TV2FPT0WU
J-RT3-T3-5 NHrvfXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HzW2lEPTB;Nj60OkBvVQ>? NGPncnVUSU6JRWK=
KALS-1 NUDVRng{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTZwNU[gcm0> M{XaV3NCVkeHUh?=
no-10 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFL2VoJKSzVyPUeuNlkhdk1? NETwSpVUSU6JRWK=
SK-NEP-1 NYj4O5ExT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjpWZRtUUN3ME24Mlc6KG6P M3v3OnNCVkeHUh?=
L-540 NYnOXFlIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1LFN2lEPTB;MUCuOFIhdk1? NXm5flBSW0GQR1XS
JiyoyeP-2003 NUDvOFlDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGniWItKSzVyPUGwMlk1KG6P M1LOTHNCVkeHUh?=
HH NU\W[3JKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfLVnVTUUN3ME2xNU4{QSCwTR?= NHHVfXRUSU6JRWK=
SR NVLFd5hvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFzLkS1JI5O NVX5bJF6W0GQR1XS
QIMR-WIL MnTuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXubldKSzVyPUGxMlg2KG6P MWPTRW5ITVJ?
A4-Fuk M4qwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF|LkGyJI5O Mn\6V2FPT0WU
CESS M1\sWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTF|LkGzJI5O M{fqWHNCVkeHUh?=
KE-37 NEDGe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUP2VVdbUUN3ME2xOk4xPyCwTR?= NHrNXIJUSU6JRWK=
SK-UT-1 MkXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\HVYlKSzVyPUG2MlgyKG6P MXHTRW5ITVJ?
SIG-M5 NXjzd2lGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHn5UmFKSzVyPUG3MlI2KG6P MXzTRW5ITVJ?
HT M4XheWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF5Lk[gcm0> MYXTRW5ITVJ?
DEL M{LSVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\FR5RDUUN3ME2xO{46QSCwTR?= MnewV2FPT0WU
SK-PN-DW NYLqR5E5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jDTmlEPTB;MkCuNlMhdk1? MYnTRW5ITVJ?
RPMI-8402 Ml3JS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTJzLke3JI5O M{nrOXNCVkeHUh?=
RPMI-6666 NGjv[IlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ2LkSyJI5O NHfpOmpUSU6JRWK=
NCI-H720 NEHSSIpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;RXHVKSzVyPUK1MlQyKG6P NEnON29USU6JRWK=
EW-16 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWDaXZZLUUN3ME2yOk45PyCwTR?= NWS3fZpUW0GQR1XS
BL-70 M4\MfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml7ZTWM2OD1{OD6zPEBvVQ>? MVzTRW5ITVJ?
SF126 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXlTWM2OD1|MD6zPEBvVQ>? M4\pZ3NCVkeHUh?=
BC-1 NUO2eW1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TtNmlEPTB;M{GuNlYhdk1? Mlr4V2FPT0WU
MHH-PREB-1 NHvSXHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3j2SmlEPTB;M{KuOFQhdk1? NV\kdphEW0GQR1XS
A101D MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;KS2lEPTB;M{KuOlIhdk1? M3jTb3NCVkeHUh?=
NMC-G1 MkL3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NImxWHBKSzVyPUOzMlY4KG6P NWmz[oxWW0GQR1XS
LB1047-RCC MljXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTN2Lk[5JI5O MUTTRW5ITVJ?
EM-2 NVXpe|UxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTN6LkWzJI5O NXGwOW1QW0GQR1XS
COLO-684 Mle2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPISVdKSzVyPUO5Mlghdk1? NFPFbnlUSU6JRWK=
Becker M3Hv[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2jxdmlEPTB;NEGuNFUhdk1? MkLXV2FPT0WU
BL-41 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jQTWlEPTB;NEOuOlYhdk1? MW\TRW5ITVJ?
MDA-MB-134-VI Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXLJR|UxRTR2LkCyJI5O NWLrVIcyW0GQR1XS
L-363 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTR2LkezJI5O MlfGV2FPT0WU
ECC4 NGnRV5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjtTWM2OD12ND63PEBvVQ>? NUnuW3d6W0GQR1XS
A388 M1u2Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFG3cW5KSzVyPUS0MlgzKG6P NUX1XnRsW0GQR1XS
HEL MmLaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrMR2VqUUN3ME20PU44QSCwTR?= NULveVhKW0GQR1XS
RKO Ml7kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTVyLkK5JI5O NGKyUnJUSU6JRWK=
KINGS-1 NVTnR|NxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP5R5F3UUN3ME21NU42PSCwTR?= MWrTRW5ITVJ?
EB-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3OflFKSzVyPUWyMlY4KG6P MVfTRW5ITVJ?
ARH-77 M4X6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTV{Lkigcm0> MWDTRW5ITVJ?
GCIY NVLrVYk6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PjOmlEPTB;NUOuOFYhdk1? M{PnXXNCVkeHUh?=
NCI-H1304 MmrxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvRemExUUN3ME21O{4zOiCwTR?= Mn\oV2FPT0WU
KARPAS-299 NIfqboZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzneo5KSzVyPU[xMlgzKG6P MXHTRW5ITVJ?
IA-LM M{TYd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTZ6LkGzJI5O NEf1OpVUSU6JRWK=
GI-1 NHe2[ZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfSTpVjUUN3ME23NE4{QSCwTR?= NHzzbIhUSU6JRWK=
TE-11 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTd5LkG3JI5O NHX5VGpUSU6JRWK=
LS-411N MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nIXmlEPTB;N{euOVchdk1? NW[xN3hpW0GQR1XS
no-11 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXhOnZKSzVyPUizMlI1KG6P MmLRV2FPT0WU
MV-4-11 NV;POYs3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoWwTWM2OD16Mz63N{BvVQ>? MWTTRW5ITVJ?
BV-173 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHyTWM2OD16Mz65O{BvVQ>? NEfWdIlUSU6JRWK=
CMK NUDzclQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkS0TWM2OD16ND6xOkBvVQ>? MmniV2FPT0WU
LC4-1 M4jlR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{LKVGlEPTB;OE[uO|Ihdk1? NF;vN|NUSU6JRWK=
COR-L279 NWXsWpRQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLifINpUUN3ME24O{4zPSCwTR?= MlGxV2FPT0WU
NCI-H209 NIqyPZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTh5LkSxJI5O M1zJWXNCVkeHUh?=
Raji MoDYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m2cGlEPTB;OEmuO|Ihdk1? NYWwXmRwW0GQR1XS
LB996-RCC Mn;5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnQUXc3UUN3ME25N{41OyCwTR?= MnLWV2FPT0WU
NCI-H526 M4jifGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFf0OI9KSzVyPUmzMlU6KG6P NHO3NopUSU6JRWK=
KGN M{LwVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoG4TWM2OD17Nj6yPUBvVQ>? MknMV2FPT0WU
MOLT-4 Ml3XS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnK2TWM2OD17Nj63PUBvVQ>? NFnuXZBUSU6JRWK=
PF-382 Ml7BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPETWM2OD17Nj63PUBvVQ>? Ml7JV2FPT0WU
BC-3 NWHLNmY2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnDZZlKSzVyPUm5MlE5KG6P MorkV2FPT0WU
KARPAS-422 M3K5fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvvWo1KSzVyPUGwNk4xQSCwTR?= MljuV2FPT0WU
SBC-1 NGnaN4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTyTWM2OD1zMEeuO|Uhdk1? NUWxcFNbW0GQR1XS
LC-1F M4XQe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1TGSmlEPTB;MUC4MlA2KG6P NGHI[HZUSU6JRWK=
GB-1 NHyxb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTFyOT6wNkBvVQ>? MXvTRW5ITVJ?
SNB75 NEnhWVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfUPItDUUN3ME2xNVkvPjlibl2= NFjsUYhUSU6JRWK=
BB65-RCC M3SzeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jacGlEPTB;MUG5Mlk{KG6P MkPjV2FPT0WU
NCI-N87 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4rMfWlEPTB;MUKxMlk5KG6P NILqU4ZUSU6JRWK=
IST-MEL1 NEPubGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHrwNJBKSzVyPUGyNk4{QCCwTR?= NWK0Z4hTW0GQR1XS
HOP-62 MnX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUDKdlE5UUN3ME2xNlYvQDlibl2= M1T6PHNCVkeHUh?=
ACN M1fubWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF2Nj63OUBvVQ>? MVLTRW5ITVJ?
DMS-114 NFHsSIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmnXTWM2OD1zNUCuOlchdk1? MUfTRW5ITVJ?
MLMA MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3PWTWlEPTB;MUW5Mlg5KG6P NUnwNI8xW0GQR1XS
HT-144 Mn3QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF4NT60N{BvVQ>? M2Lxc3NCVkeHUh?=
C2BBe1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fTOWlEPTB;MU[3Mlc3KG6P Mki1V2FPT0WU
L-428 NYTiTnV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;pTWM2OD1zN{euO{BvVQ>? NXn5dFFmW0GQR1XS
DU-4475 M33Ec2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fEN2lEPTB;MUi3MlY5KG6P M{n6VXNCVkeHUh?=
CP67-MEL M3OyUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYfuW444UUN3ME2xPVkvOzhibl2= M1LoUXNCVkeHUh?=
MEG-01 NGO3SoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTJyMT65OkBvVQ>? NH;BSFdUSU6JRWK=
IST-SL2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV7sNXlKUUN3ME2yNFgvPjNibl2= NWr3UJFRW0GQR1XS
ES8 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfsXFRKSzVyPUKyOU46PCCwTR?= MVjTRW5ITVJ?
COLO-800 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1vR[GlEPTB;MkO1MlI5KG6P M1Pzc3NCVkeHUh?=
MFH-ino M3nsfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MluxTWM2OD1{M{WuPFQhdk1? NX\wfW9wW0GQR1XS
OVCAR-4 Mkf6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTJ|Nz6yOEBvVQ>? MlTPV2FPT0WU
PSN1 NInLZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGDZdXBKSzVyPUK0Nk44OSCwTR?= Ml3XV2FPT0WU
EW-12 NYrsV2t3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPLTI1RUUN3ME2yOFMvOSCwTR?= M2LIW3NCVkeHUh?=
HCC1599 MmTVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrYWGJkUUN3ME2yOlEvPDdibl2= MmLlV2FPT0WU
SJSA-1 NF6x[4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2C2VWlEPTB;MkexMlQ3KG6P M2XQUnNCVkeHUh?=
ST486 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn76TWM2OD1{OU[uNVQhdk1? MXfTRW5ITVJ?
NOMO-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\BTWM2OD1|MECuNlEhdk1? MonoV2FPT0WU
MN-60 NIHEWJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITTbGlKSzVyPUOwOU4{OiCwTR?= MWXTRW5ITVJ?
HCC1187 M4jx[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7LTWM2OD1|MEeuNlUhdk1? MmjyV2FPT0WU
SW982 NYLsN3psT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXGxS2E1UUN3ME2zNVQvPzVibl2= NF3oe|NUSU6JRWK=
LB647-SCLC MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH;U[|lKSzVyPUOyPE44OSCwTR?= MnzVV2FPT0WU
HC-1 M1LNPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTN|NT61JI5O M3;6XXNCVkeHUh?=
EHEB M3vhNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTN|Nz61NkBvVQ>? MYfTRW5ITVJ?
TUR M4TTSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DuNmlEPTB;M{[zMlk2KG6P MYDTRW5ITVJ?
LU-139 NXXhfm9xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\TfmlEPTB;M{e4MlAzKG6P NV;MNXRoW0GQR1XS
NB1 NHS0XYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2q0NmlEPTB;M{i0MlQ2KG6P M{LEU3NCVkeHUh?=
BB30-HNC NXq3[ZRPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDTTXlXUUN3ME2zPFgvOzJibl2= NI\6ZYRUSU6JRWK=
HAL-01 NX7lOolPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPtTWM2OD1|OEmuNlYhdk1? NHfGS41USU6JRWK=
K5 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHP5R4NKSzVyPUSxNU4{PyCwTR?= MX;TRW5ITVJ?
MZ2-MEL MmLyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWjJR|UxRTRzMz62OEBvVQ>? MnLlV2FPT0WU
RXF393 NIfWU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTRzNj60OUBvVQ>? NHW4bVBUSU6JRWK=
NCI-H1648 M3vac2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLMTWM2OD12MUeuOVMhdk1? NWjoZmNCW0GQR1XS
TE-12 M2rOU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDrUZR5UUN3ME20N|QvOjZibl2= MXLTRW5ITVJ?
EoL-1- MlX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTR|Nz65PEBvVQ>? NF:1dopUSU6JRWK=
JAR MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MknJTWM2OD12M{iuOlIhdk1? NULlRpFQW0GQR1XS
DSH1 NXnCV|N3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkTmTWM2OD12NUiuPVEhdk1? MnTmV2FPT0WU
NCI-H187 NF3mSmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4ftWmlEPTB;NE[yMlgyKG6P NYm0[FA5W0GQR1XS
HCE-4 NFfFV|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MY\JR|UxRTR5Nz62OkBvVQ>? MWXTRW5ITVJ?
8-MG-BA NXHEbHhCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PTWGlEPTB;NUixMlUzKG6P NHHZ[GZUSU6JRWK=
KLE M1OxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXyc49KSzVyPUW4OU4zKG6P NWGyb3ZUW0GQR1XS
KNS-42 NYn0e41nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTV6Nj64NUBvVQ>? MU\TRW5ITVJ?
MSTO-211H MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHTJUldKSzVyPU[wPU44PCCwTR?= M4W1eXNCVkeHUh?=
GDM-1 MoOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnj0TWM2OD14MUSuNFkhdk1? MYTTRW5ITVJ?
TE-1 MljES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrueplKSzVyPU[0Ok4yOiCwTR?= NXfHUYl7W0GQR1XS
BT-474 MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXHJR|UxRTZ2Nz6wOkBvVQ>? MWHTRW5ITVJ?
KARPAS-45 MlrvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3juXWlEPTB;NkS3MlYhdk1? NGXzbFBUSU6JRWK=
MOLT-16 MmLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OycmlEPTB;NkS3Mlk{KG6P NI\MfVdUSU6JRWK=
KURAMOCHI M4fk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTZ3Nz61NUBvVQ>? MnfVV2FPT0WU
K-562 NFzGZWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XXRWlEPTB;Nk[5MlUyKG6P NXPObVhNW0GQR1XS
EKVX NUnGXFg5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITqU4xKSzVyPU[3Nk44OSCwTR?= M1nCSnNCVkeHUh?=
GAK NUPOUWhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWC3TmZXUUN3ME22O|UvOyCwTR?= MYDTRW5ITVJ?
NCI-SNU-5 NUnxXXZXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkfBTWM2OD14OUCuNFEhdk1? Ml;KV2FPT0WU
NCI-H2126 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{O1bWlEPTB;N{K2Mlg4KG6P MnjSV2FPT0WU
CTV-1 NVmw[25XT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTd2ND65JI5O Ml23V2FPT0WU
SW962 NU\GTow{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTd2OD60OEBvVQ>? MVHTRW5ITVJ?
MONO-MAC-6 NV7ydm5RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;qTWM2OD15NU[uPVMhdk1? NWi4PYVnW0GQR1XS
NCI-H748 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoeyTWM2OD15NUiuPVkhdk1? M1uwfnNCVkeHUh?=
NCI-H524 M2[2Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7aTWM2OD15OECuO|Mhdk1? M1z6[3NCVkeHUh?=
LS-123 NFrHOlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTd7NT62PUBvVQ>? MmPUV2FPT0WU
NB7 M4PjfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXfRRnZDUUN3ME24NVQvOTRibl2= M4fBRnNCVkeHUh?=
LS-1034 MoLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1jhPGlEPTB;OEK4Mlk5KG6P NF;GTplUSU6JRWK=
TE-5 NV7BXm17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDMZlJKSzVyPUi4N{42PiCwTR?= NWLBSm0zW0GQR1XS
A704 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mln2TWM2OD16OUmuNVUhdk1? NVSwb2QyW0GQR1XS
TK10 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DiWmlEPTB;OUG2MlA{KG6P M4e4cnNCVkeHUh?=
NCI-H345 NGXwPG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{LOU2lEPTB;OUSzMlIzKG6P NInLR|JUSU6JRWK=
CGTH-W-1 NHvXcI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHKTWM2OD17NEiuNVMhdk1? NITCU5pUSU6JRWK=
NCI-H510A MlXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1P5OWlEPTB;OUi1MlEzKG6P NGDSfZZUSU6JRWK=
NCI-H1963 NWjldZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXKxNoRqUUN3ME2xMlA{Ojl{IN88US=> MULTRW5ITVJ?
SCC-3 M4nhUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXvjbHRSUUN3ME2xMlA{PDF2IN88US=> NHGwXG1USU6JRWK=
EW-11 M4O0cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOzTWM2OD1zLkC4O|Q{KM7:TR?= NUPOUZRDW0GQR1XS
CPC-N M4nTUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXTdFZKSzVyPUGuNFg5KM7:TR?= Mnq5V2FPT0WU
NCI-H1417 Mn\GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\6SHBqUUN3ME2xMlEzOjZizszN M1\pfnNCVkeHUh?=
DG-75 M{Hibmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rye2lEPTB;MT6xOlI5PSEQvF2= NWH5b2UzW0GQR1XS
HD-MY-Z NX3VNYQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnL2TWM2OD1zLkG2OFE3KM7:TR?= M3TBeHNCVkeHUh?=
ATN-1 NE[5bYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDvOWRKSzVyPUGuNlYzODlizszN MXnTRW5ITVJ?
KM-H2 M2fxNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MonWTWM2OD1zLkK2OFA5KM7:TR?= NXrVWI9sW0GQR1XS
NCI-H2081 NHjxWllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwMk[2N|ch|ryP MVjTRW5ITVJ?
HL-60 NVrzOZZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTJTWM2OD1zLkK2PVU6KM7:TR?= MofMV2FPT0WU
DB NYT5NI9zT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMkeyOFIh|ryP NIriSXVUSU6JRWK=
NCI-H1522 NYDFXHM{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFnlWoRKSzVyPUGuNlg5QDdizszN NEHyWFBUSU6JRWK=
AM-38 M{PVVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\PSWlEPTB;MT6zNFczKM7:TR?= NIPGfGdUSU6JRWK=
NCI-H446 Mmq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XlV2lEPTB;MT6zNlEzOSEQvF2= MULTRW5ITVJ?
SU-DHL-1 M{f2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPHTVBKSzVyPUGuN|I5ODFizszN NHfGUo5USU6JRWK=
NH-12 MoToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfITWM2OD1zLkO2N|c1KM7:TR?= NE\TOolUSU6JRWK=
DMS-79 MmPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2LOOWlEPTB;MT6zOlg3PiEQvF2= M2TLTnNCVkeHUh?=
NCI-H716 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjvcGlbUUN3ME2xMlM5QTh4IN88US=> M3rNeXNCVkeHUh?=
ML-2 M{jtTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWrJR|UxRTFwNEG1Nlkh|ryP MYfTRW5ITVJ?
NB10 NGTk[IpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NY\wfXZoUUN3ME2xMlQ3PjN{IN88US=> NIjuW5VUSU6JRWK=
ONS-76 M1yxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVvJR|UxRTFwNUO1Olkh|ryP NEmwd3pUSU6JRWK=
LOUCY NVT6d5d2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGjzUXhKSzVyPUGuOVQ3PTdizszN MonmV2FPT0WU
SCLC-21H MkLsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTaTWM2OD1zLkW4OVgzKM7:TR?= NEfPfG9USU6JRWK=
TGW MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTFwNkO5O|Uh|ryP NFvhPIxUSU6JRWK=
LXF-289 MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFwN{OyOlgh|ryP MYTTRW5ITVJ?
BB49-HNC M1zpTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTFwN{O1PFYh|ryP NEPZRYpUSU6JRWK=
NCI-H747 NYnpe2x1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTFwN{WzOFYh|ryP MXLTRW5ITVJ?
LU-165 MkPxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjpWotKSzVyPUGuPFQ6QDZizszN NUPFfVc3W0GQR1XS
OMC-1 MnTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS3XHU{UUN3ME2xMlk2ODZ4IN88US=> MY\TRW5ITVJ?
RCC10RGB NWHYS|dPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX\JR|UxRTFwOUW4NVch|ryP NIXafG1USU6JRWK=
SW684 M4rPTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEDQO2lKSzVyPUGuPVYxQTlizszN NXfkPVY1W0GQR1XS
TE-8 MmTiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDDd3ZKSzVyPUKuNFU2PTlizszN NYL1ZoFoW0GQR1XS
SK-N-DZ MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH6R4pUUUN3ME2yMlE{Ojd2IN88US=> NGTiOnNUSU6JRWK=
EVSA-T M3uzXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJwMUezNVUh|ryP NUf5Wm4zW0GQR1XS
KASUMI-1 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHRc4hKSzVyPUKuNVg5OTVizszN MkXiV2FPT0WU
NKM-1 NUHXeJpjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n0cGlEPTB;Mj6yOVQ4OiEQvF2= NFqxdVlUSU6JRWK=
CAL-148 NUP1e29RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLPfJNKSzVyPUKuN|M3OTRizszN MlH0V2FPT0WU
NCI-H64 NYHFWpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJwM{SyN|Ih|ryP MYTTRW5ITVJ?
KNS-81-FD NV7jU2x5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33CS2lEPTB;Mj6zOlYzKM7:TR?= MoOyV2FPT0WU
KM12 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LLNmlEPTB;Mj60NFg{QSEQvF2= MmnDV2FPT0WU
SW954 Mln3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYqyNZRmUUN3ME2yMlQ4Pzd7IN88US=> MXPTRW5ITVJ?
NCI-H1395 M13HUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHHYeINKSzVyPUKuOVI3PDVizszN NXL1OJBMW0GQR1XS
DJM-1 MknkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXqSGhKSzVyPUKuOlA3OyEQvF2= NYOxbYJoW0GQR1XS
COLO-668 NI\FcWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVXub3dVUUN3ME2yMlgzPjl3IN88US=> M2DndHNCVkeHUh?=
NCI-H1436 MnfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTJwOEW2NVUh|ryP MX\TRW5ITVJ?
LB2241-RCC MkTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkWzTWM2OD1{Lki2PFM6KM7:TR?= NELVeI5USU6JRWK=
GT3TKB MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnzjTWM2OD1{Lki5NFU2KM7:TR?= MmTCV2FPT0WU
COLO-824 NXja[W05T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\YPYpKSzVyPUKuPFk4PjhizszN M{XKeXNCVkeHUh?=
ES1 NVfsO45xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTwTWM2OD1{Lki5PFc6KM7:TR?= MVrTRW5ITVJ?
LB771-HNC M1nHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjmZpAzUUN3ME2yMlkxQTR4IN88US=> M{TPUnNCVkeHUh?=
GI-ME-N MojiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\UZVBxUUN3ME2zMlAxQTB2IN88US=> MVrTRW5ITVJ?
NALM-6 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{e4bWlEPTB;Mz6wNFk{OyEQvF2= NIfJfIFUSU6JRWK=
LU-134-A NXPoSIxZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PJTWlEPTB;Mz6wOVQzPSEQvF2= NF\h[oVUSU6JRWK=
DMS-153 MmS2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGe2dXRKSzVyPUOuNFU5OjRizszN NUP0c|VnW0GQR1XS
MZ1-PC NIr6bYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\qTWM2OD1|LkC5NFc5KM7:TR?= NEDIOllUSU6JRWK=
NCI-H1155 NVzYZXZwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoT4TWM2OD1|LkGxOlEh|ryP MnvEV2FPT0WU
CAS-1 NEOwN|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUfJR|UxRTNwMUO3NFch|ryP NWG0So1RW0GQR1XS
D-502MG M{HPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTRbJhDUUN3ME2zMlE1OzlizszN Mo\NV2FPT0WU
NCI-H2141 M1\2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLxTWM2OD1|LkG3OFUzKM7:TR?= NFuzdnZUSU6JRWK=
NB6 Moi2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vJRmlEPTB;Mz6xPFI2QSEQvF2= NUDsdVJZW0GQR1XS
NCCIT MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTNwMkG4NFkh|ryP NYLnS5M1W0GQR1XS
NB69 M3TEd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIOydmNKSzVyPUOuN|E5QTFizszN MX3TRW5ITVJ?
JVM-2 M333S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVPtd455UUN3ME2zMlM3PDN|IN88US=> M3\lW3NCVkeHUh?=
K052 NGC4fXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fF[mlEPTB;Mz6zO|k3QCEQvF2= M1ThNXNCVkeHUh?=
HCC2157 M4PFXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFPqOlBKSzVyPUOuOVMzOjhizszN Ml\aV2FPT0WU
KMOE-2 MkXCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjWSpFKSzVyPUOuOVQzPDJizszN NEXiNnBUSU6JRWK=
SF268 NHfTR4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MorjTWM2OD1|LkexOVU1KM7:TR?= NH;lZnBUSU6JRWK=
CHP-126 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoG4TWM2OD1|Lke2OFU5KM7:TR?= M3\YdHNCVkeHUh?=
CP66-MEL NGe2c|ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUH4TGZSUUN3ME2zMlc6ODl2IN88US=> M2LDO3NCVkeHUh?=
NCI-H69 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fxV2lEPTB;ND6wNVk{PiEQvF2= NVnvV2lzW0GQR1XS
A253 NX:zWWFZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkPoTWM2OD12LkCyNVAyKM7:TR?= NWjaSHg{W0GQR1XS
NB14 NXrLTWtzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO2U2JKSzVyPUSuNVA1PzlizszN MnjWV2FPT0WU
NCI-H1694 M{m0UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXxeplKSzVyPUSuNVMyOTJizszN MmXBV2FPT0WU
NCI-H2196 MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTRwMUexOlkh|ryP MVPTRW5ITVJ?
TE-9 NIfXfplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlmyTWM2OD12LkG3OVgzKM7:TR?= NIPwc4lUSU6JRWK=
D-283MED NXryWYRiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXLfJhKSzVyPUSuNVg5PCEQvF2= NI\G[|lUSU6JRWK=
OCI-AML2 M{PzRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEezSlNKSzVyPUSuNVk1QDlizszN MYfTRW5ITVJ?
D-263MG MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3QTWM2OD12LkKyPVYyKM7:TR?= MX3TRW5ITVJ?
MPP-89 MkfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlfMTWM2OD12LkK3N|A1KM7:TR?= M4jmOXNCVkeHUh?=
LAMA-84 M2TMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXPT4puUUN3ME20MlMxPDJzIN88US=> MmfwV2FPT0WU
LB373-MEL-D MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYe3TGs5UUN3ME20MlM3Pzh7IN88US=> NHTlbllUSU6JRWK=
UACC-257 NU\1[nhyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTRwM{m1N|Qh|ryP NG\TXGdUSU6JRWK=
MC-CAR Ml7lS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfNTWM2OD12LkSzPVkh|ryP NEW5TFBUSU6JRWK=
COLO-320-HSR MnexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknmTWM2OD12LkS0OFI4KM7:TR?= MlPWV2FPT0WU
P30-OHK NEjYSI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTRwNk[1PFEh|ryP NHnCclhUSU6JRWK=
UACC-812 NYDBblV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXhOZAxUUN3ME20MlY6OTZzIN88US=> NXfTb3J6W0GQR1XS
CTB-1 M{\lUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXfJR|UxRTRwN{G1OVUh|ryP NWDVcpQ5W0GQR1XS
ALL-PO M1TUPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfx[FVKSzVyPUSuPFQxPzdizszN NWTtPFg5W0GQR1XS
SK-MEL-2 M{fYeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXNdnZDUUN3ME20Mlg3QTV3IN88US=> M1rwU3NCVkeHUh?=
TC-YIK NILt[WVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHqZXBKSzVyPUSuPVc6PDJizszN NH\XNolUSU6JRWK=
NCI-H1882 MnLoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkKzTWM2OD13LkCyNFAyKM7:TR?= NYCydWl5W0GQR1XS
MHH-CALL-2 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\ofWlEPTB;NT6wOVA1OiEQvF2= NVGyOG06W0GQR1XS
U-87-MG M4DlRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUC4SlRbUUN3ME21MlA6PDZ4IN88US=> MlHwV2FPT0WU
NCI-H1092 MkXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTVwMk[1OVUh|ryP MVPTRW5ITVJ?
TE-441-T NHvwUVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmS1TWM2OD13LkK3PFIh|ryP MontV2FPT0WU
SK-MEL-1 NYXsPVhLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVPpfZlJUUN3ME21MlI6ODR2IN88US=> NFLrOHlUSU6JRWK=
EW-22 NVG1S2U5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYDJR|UxRTVwMkm0OlYh|ryP MofVV2FPT0WU
MZ7-mel NEezZWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3jJPWlEPTB;NT60NFY6OSEQvF2= NGCxTIxUSU6JRWK=
LP-1 M3;pd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTVwNEGyPVEh|ryP NWLibXhFW0GQR1XS
NCI-SNU-16 MlPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2rqfWlEPTB;NT62OFA4PCEQvF2= NGjJdWZUSU6JRWK=
LU-65 NXKxOZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXNV2ZTUUN3ME21Mlc3Ozd|IN88US=> MWrTRW5ITVJ?
CW-2 NWL3VWZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWHTRop3UUN3ME21Mlg2QTV7IN88US=> NXPP[mE2W0GQR1XS
WSU-NHL NGHDTphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHKWmxKSzVyPUWuPVUyPzRizszN M{LPXHNCVkeHUh?=
IST-MES1 NI\KeIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mlu0TWM2OD13Lkm1OFQ{KM7:TR?= NU\GfXFiW0GQR1XS
U-266 NVjsWW54T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXGcZY5UUN3ME21Mlk5OjB{IN88US=> MoT3V2FPT0WU
TALL-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{K0XWlEPTB;Nj6xOFY5QCEQvF2= Mmr1V2FPT0WU
Calu-6 NYDGUphrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrDTWM2OD14LkG1N|E3KM7:TR?= MXvTRW5ITVJ?
MMAC-SF MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX[3S|J{UUN3ME22MlE5PTV4IN88US=> M1jWTnNCVkeHUh?=
NCI-H82 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW3UWNKSzVyPU[uNlA1QDlizszN M3ywUnNCVkeHUh?=
RS4-11 M{Xrc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVTCbZpDUUN3ME22MlI2QDl5IN88US=> NXzU[VVjW0GQR1XS
SNU-C2B M3HiTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTZwNEC5Olkh|ryP M4G1RnNCVkeHUh?=
BOKU MlH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{XRSmlEPTB;Nj60O|U6PyEQvF2= NHjDd4lUSU6JRWK=
C8166 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfxTWM2OD14LkW1PVEzKM7:TR?= NFjpPWFUSU6JRWK=
D-247MG M3LBXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\aWZJKSzVyPUeuNFQ{PDdizszN MnvjV2FPT0WU
EW-18 NHrrVWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTdwMEeyPVIh|ryP MYXTRW5ITVJ?
KG-1 MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXKxS4U2UUN3ME23MlYzPzN6IN88US=> MoL0V2FPT0WU
REH M1\Ncmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3uxZWlEPTB;Nz62PFExQSEQvF2= NGjzPFlUSU6JRWK=
U-698-M M{TJ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTdwOESzNVUh|ryP MV;TRW5ITVJ?
KP-N-RT-BM-1 MlfPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MojOTWM2OD15LkmzNFI6KM7:TR?= MWXTRW5ITVJ?
MS-1 MnfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DVdWlEPTB;Nz65OlA1OSEQvF2= M{XkU3NCVkeHUh?=
SNU-C1 NGDKSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqzTWM2OD15Lkm4NVkzKM7:TR?= MXjTRW5ITVJ?
SK-MM-2 MkewS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzNOG9KSzVyPUiuNlYxPjVizszN NHTrPYRUSU6JRWK=
LAN-6 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDaWZZwUUN3ME24MlMxODBzIN88US=> NH2wfIVUSU6JRWK=
NEC8 NVzUZmdNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmi5TWM2OD16LkOwOlkyKM7:TR?= NF7tT25USU6JRWK=
NCI-H1770 NX;LUW17T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3u5bGlEPTB;OD6zPFAxOiEQvF2= MUTTRW5ITVJ?
D-336MG NHvxZnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2DYSGlEPTB;OD60NFEyPiEQvF2= NGjHcFNUSU6JRWK=
COLO-829 M{\Odmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml76TWM2OD16LkS4PFc6KM7:TR?= MXLTRW5ITVJ?
LS-513 MnjWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1fwV2lEPTB;OD61PVU6QSEQvF2= NHezdW9USU6JRWK=
YT MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRThwNkK0Nlch|ryP NVuzUJd6W0GQR1XS
EW-24 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRThwN{[1OEDPxE1? NHj5OmxUSU6JRWK=
IST-SL1 NFHuNIZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TXSWlEPTB;OD64OlU1OyEQvF2= MV;TRW5ITVJ?
CA46 NHf1e4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVHYVIkzUUN3ME24Mlk2ODl6IN88US=> MY\TRW5ITVJ?
NCI-H1838 NVewRnc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXq4VGFtUUN3ME24Mlk5PjB{IN88US=> Ml[2V2FPT0WU
NCI-H719 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\GTWM2OD17LkK1Nlc6KM7:TR?= MoG1V2FPT0WU
HCE-T NH3mbZJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUnJR|UxRTlwM{C4OVEh|ryP NVP6dGk4W0GQR1XS
A498 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlG4TWM2OD17LkO2NVI1KM7:TR?= NXvNVYlqW0GQR1XS
LB831-BLC M3y5W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYXJR|UxRTlwN{[1NlEh|ryP MWXTRW5ITVJ?
SKM-1 NH;zTYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEXXTZVKSzVyPUmuPFU6PjNizszN NYDTb3lUW0GQR1XS
THP-1 M{HmUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\1OmlEPTB;OT65OlkyQCEQvF2= MX;TRW5ITVJ?
SHP-77 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TLc2lEPTB;MUCuOFA4KM7:TR?= MkXiV2FPT0WU
EW-3 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HVbmlEPTB;MUCuOlI5QSEQvF2= NFi5WIRUSU6JRWK=
KY821 MmHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPiTWM2OD1zMD63OlMh|ryP M3noTnNCVkeHUh?=
NCI-SNU-1 NH3DSZBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XHNWlEPTB;MUGuNFIyPyEQvF2= MYTTRW5ITVJ?
HCC2218 NHzSV21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3GSVVKSzVyPUGxMlM6QDZizszN M3m3ZnNCVkeHUh?=
IM-9 MmrTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjnTWM2OD1zMT61NVA3KM7:TR?= NYTJbYFHW0GQR1XS
NCI-H889 MmLqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLYNlNKSzVyPUGxMlU{OTNizszN MXLTRW5ITVJ?
HDLM-2 NX3U[GRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4HJbGlEPTB;MUKuOFE2QSEQvF2= M1fFO3NCVkeHUh?=
LB2518-MEL MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX;nZphSUUN3ME2xNk43QDF3IN88US=> MlHqV2FPT0WU
NCI-H23 MmnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmO2TWM2OD1zMz6yOFI2KM7:TR?= M{frXnNCVkeHUh?=
NB17 MnvFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vMV2lEPTB;MUOuOFU4QSEQvF2= NVP2OI1yW0GQR1XS
NCI-H322M M4XPXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXTiVoZnUUN3ME2xOE41ODZ6IN88US=> MnPPV2FPT0WU
SUP-T1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTiTWM2OD1zND60NVMh|ryP NXXuS29CW0GQR1XS
ES3 MkThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7mU2g2UUN3ME2xOU4xPzB|IN88US=> NWLaeYp3W0GQR1XS
ES5 M3ryNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIDEOHRKSzVyPUG1MlA4QDdizszN NH34S5ZUSU6JRWK=
NCI-H1650 MlTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF3LkS5O|kh|ryP NUm2XWJ6W0GQR1XS
NCI-H226 M1H5Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYXuVHZjUUN3ME2xOU45PzZ6IN88US=> MWnTRW5ITVJ?
COR-L88 NUj3cJFYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlXqTWM2OD1zNj6zNVQh|ryP MkjJV2FPT0WU
SCC-15 NXXjdIF2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{XPW2lEPTB;MU[uN|g3QSEQvF2= NGXQZWVUSU6JRWK=
GOTO MlznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PTb2lEPTB;MU[uOFc6OyEQvF2= MUPTRW5ITVJ?
SIMA NV:0U5lKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIL5cJlKSzVyPUG2MlQ5ODJizszN M3PGdnNCVkeHUh?=
NCI-H1299 NVWxTXhwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1q5NGlEPTB;MUeuNVU6OSEQvF2= Ml\VV2FPT0WU
NCI-H1581 NFP6W3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTF5LkSyNVkh|ryP MkK0V2FPT0WU
MHH-NB-11 MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT0[IFoUUN3ME2xO{46Pjh|IN88US=> MVHTRW5ITVJ?
MFM-223 MoL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\udHEzUUN3ME2xPE4xPTN6IN88US=> M{njVHNCVkeHUh?=
ES7 NUi5PWZYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;wXG1KSzVyPUG4MlU1OzFizszN NG[zNXhUSU6JRWK=
JVM-3 NV7ld21FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzSU21KSzVyPUG4MlcyPyEQvF2= NGnoem9USU6JRWK=
RL MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTJyLkO4PEDPxE1? NIL0O29USU6JRWK=
EC-GI-10 NWLye3dyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUL1bW52UUN3ME2yNU4zODRzIN88US=> M3qxRXNCVkeHUh?=
LNCaP-Clone-FGC MoHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTJzLk[3Olgh|ryP MVPTRW5ITVJ?
IMR-5 Ml3aS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV71XXk6UUN3ME2yNU45PDl2IN88US=> MlPtV2FPT0WU
KP-N-YS MlnIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{nDZmlEPTB;MkGuPFc2KM7:TR?= MlX5V2FPT0WU
Mo-T NV:3SoptT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTJ{LkKxPFUh|ryP MVjTRW5ITVJ?
NCI-H128 MkTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTJ|LkW4OVMh|ryP M3LWRXNCVkeHUh?=
RH-1 NVG3eWxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTJ|Lke4OlYh|ryP NWXs[3AxW0GQR1XS
NCI-H2171 NYfsV49NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2XLU2lEPTB;MkSuNlQ5PSEQvF2= NIDQc2xUSU6JRWK=
RPMI-8866 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\GZ2NKSzVyPUK2Mlc1OiEQvF2= M3;5dnNCVkeHUh?=
SK-N-FI NGDreVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIH2TYRKSzVyPUK3MlM5OTFizszN NGTIV2FUSU6JRWK=
LOXIMVI NYXpTGR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ5LkiwOVEh|ryP MoTHV2FPT0WU
P31-FUJ M1fQR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTNzLkWzO|Qh|ryP MlvMV2FPT0WU
KMS-12-PE MoPHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkL6TWM2OD12OT61N|AzKM7:TR?= NEnORnRUSU6JRWK=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p-mTOR(S2448)/mTOR; 

PubMed: 23991038     


MCF-7-vector and MCF-7-ZNF703 cells were treated with DMSO, 0.1 µM rapamycin, or 1 µM rapamycin for 24 hours before cell lysis. Western blot analysis of lysates using the indicated antibodies. A GAPDH antibody was used as a loading control.

23991038
Growth inhibition assay
Cell proliferation; 

PubMed: 30393233     


(A) Effect of Rapamycin treatment on SK-N-SH cell proliferation. (B) Effect of Rapamycin treatment on SH-SY5Y cell proliferation. Rapamycin, except treatment of 10 µM for 12 h, can obviously inhibited proliferation of NB cells compared with corresponding control group (P<0.05). (*) indicates statistically significant difference with P<0.05.

30393233
Histomorphology
Haematoxylin & Eosin; 

PubMed: 28418837     


Representative pictures of H&E-stained U87MG cells. The fusiform cell body observed in control cells A. disappears in cells exposed to increasing doses of rapamycin for 24 h B.-E. Rapamycin produces a dose-dependent increase in the diameter of the cell body which develops a pyramidal shape. 1 nM (B); 10 nM (C); 100 nM (D); 1 μM (E) of rapamycin exposure.

28418837
Immunofluorescence
NeuN; 

PubMed: 28418837     


Immune-fluorescence of U87MG cells treated with vehicle A.-D. and rapamycin at the dose of 10 nM E.-H.; 100 nM I.-L.; 1 μM M.-P. In the first line cells were stained for the late post-mitotic neuronal marker NeuN. In the second line cells were stained for the nuclear dye DAPI. In the third line the merging between NeuN (green) and DAPI (blue) fluorescence is shown. In the fourth line a high magnification of the squared insert of line three is shown.

p62/Beclin; 

PubMed: 28819214     


(C,D) Rapamycin treatment reduced the aggregate level of p62 and Beclin 1 in cardiomyocytes. NRVCs were transduced with Ad-Nef or Ad-null for 48 hours and cells were fixed with 4% PFA. Fixed cells were stained with p62 and Beclin 1 antibody. 

28418837 28819214
ELISA
Type III collagen/Fibronectin; 

PubMed: 23364979     


(A) Rapamycin inhibits TGF-β1-induced type III collagen level in the culture medium of human lung fibroblast, evidenced by ELISA. Type III collagen level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. No significant difference was found between different concentration groups of rapamycin. (B) Rapamycin inhibits TGF-β1-induced fibronectin level in the culture medium of human lung fibroblast, shown by ELISA. Fibronectin level after 24-h incubation with medium alone (control), 0.01, 0.1, 1.0, and 10 ng/mL rapamycin and 10 ng/mL TGF-β1. Values are mean of three independent experiments. No significant difference was found between different concentration groups of rapamycin. *p<0.05 vs. control; †p<0.05 vs. TGF-β1 group. TGF-β1, transforming growth factor β1.

23364979
In vivo Treatment with Rapamycin in vivo specifically blocks targets known to be downstream of mTOR such as the phosphorylation and activation of p70S6K and the release of inhibition of eIF4E by PHAS-1/4E-BP1, leading to complete blockage of the hypertrophic increases in plantaris muscle weight and fibre size. [4] Short-term Rapamycin treatment, even at the lowest dose of 0.16 mg/kg, produces profound inhibition of p70S6K activity, which correlates with increased tumor cell death and necrosis of the Eker renal tumors. [5] Rapamycin inhibits metastatic tumor growth and angiogenesis in CT-26 xenograft models by reducing the production of VEGF and blockage of VEGF-induced endothelial cell signaling. [6] Rapamycin treatment at 4 mg/kg/day significantly reduces tumor growth of C6 xenografts, and tumor vascular permeability. [7]

Protocol

Kinase Assay:

[1]
- Collapse

Immunoblotting for the mTOR kinase assay:

HEK293 cells are plated at 2-2.5×105 cells/well of a 12-well plate and serum-starved for 24 hours in DMEM. Cells are treated with increasing concentrations of Rapamycin (0.05-50 nM) for 15 minutes at 37 °C. Serum is added to a final concentration of 20% for 30 minutes at 37 °C. Cells are lysed, and cell lysates are separated by SDS-PAGE. Resolved proteins are transferred to a polyvinylidene difluoride membrane and immunoblotted with a phosphospecific primary antibody against Thr-389 of p70 S6 kinase. Data are analyzed using ImageQuant and KaleidaGr
Cell Research:

[3]
- Collapse
  • Cell lines: U87-MG, T98G, and U373-MG
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Rapamycin for 72 hours. For the assessment of cell viability, cells are collected by trypsinization, stained with trypan blue, and the viable cells in each well are counted. For the determination of cell cycle, cells are trypsinized, fixed with 70% ethanol, and stained with propidium iodide using a flow cytometry reagent set. Samples are analyzed for DNA content using a FACScan flow cytometer and CellQuest software. For apoptosis detection, cells are stained with the terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) technique using an ApopTag apoptosis detection kit. To detect the development of acidic vesicular organelles (AVO), cells are stained with acridine orange (1 μg/mL) for 15 minutes, and examined under a fluorescence microscope. To quantify the development of AVOs, cells are stained with acridine orange (1 μg/mL) for 15 minutes, removed from the plate with trypsin-EDTA, and analyzed using the FACScan flow cytometer and CellQuest software. To analyze the autophagic process, cells are incubated for 10 minutes with 0.05 mM monodansylcadaverine at 37 °C and are then observed under a fluorescence microscope.


    (Only for Reference)
Animal Research:

[7]
- Collapse
  • Animal Models: Athymic Nu/Nu mice inoculated subcutaneously with VEGF-A-expressing C6 rat glioma cells
  • Dosages: ~4 mg/kg/day
  • Administration: Injection i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 20 mg/mL (21.87 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 914.18
Formula

C51H79NO13
CAS No. 53123-88-9
Storage powder
in solvent
Synonyms AY 22989，NSC-2260804
Smiles CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Dosage mg/kg Average weight of animals g Dosing volume per animal ul Number of animals
Step 2: Enter the in vivo formulation ()
% DMSO % % Tween 80 % ddH2O
CalculateReset

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04448873 Recruiting Drug: Sirolimus Kaposiform Hemangioendothelioma|Kasabach-Merritt Syndrome Children''s Hospital of Fudan University July 1 2020 Phase 4
NCT04172922 Not yet recruiting Drug: Topical Sirolimus Vascular Anomaly Nemours Children''s Clinic December 1 2019 Phase 1
NCT04128722 Active not recruiting Drug: Sirolimus Oral Liquid Product 1mg/mL Lingual Microcystic Lymphatic Malformations University Hospital Tours November 30 2019 Phase 2
NCT03433183 Recruiting Drug: Selumetinib|Drug: Sirolimus Malignant Peripheral Nerve Sheath Tumors|Neurofibromatosis 1 Sarcoma Alliance for Research through Collaboration|United States Department of Defense|AstraZeneca October 2 2019 Phase 2
NCT04348292 Recruiting Drug: Durvalumab|Drug: Sirolimus Lung Non-Small Cell Carcinoma|Stage I Lung Cancer AJCC v8|Stage IA1 Lung Cancer AJCC v8|Stage IA2 Lung Cancer AJCC v8|Stage IA3 Lung Cancer AJCC v8|Stage IB Lung Cancer AJCC v8|Stage II Lung Cancer AJCC v8|Stage IIA Lung Cancer AJCC v8|Stage IIB Lung Cancer AJCC v8|Stage IIIA Lung Cancer AJCC v8 Emory University|National Cancer Institute (NCI) October 22 2019 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

mTOR Signaling Pathway Map

mTOR Inhibitors with Unique Features

  • Pan mTOR inhibitor

    KU-0063794 : mTORC1 and mTORC2, IC50=~10 nM.

  • FDA-approved mTOR Inhibitor

    Temsirolimus (CCI-779, NSC 683864) : Approved by FDA for Renal Cell Carcinoma (RCC).

  • Newest mTOR Inhibitor

    XL388 New : Highly potent, selective, ATP-competitive inhibitor of mTOR with IC50 of 9.9 nM, 1000-fold selectivity over the closely related PI3K kinases.

  • Classic mTOR Inhibitor

    BEZ235 (NVP-BEZ235, Dactolisib) : Dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM/5 nM/7 nM/75 nM/6 nM, respectively.

Related mTOR Products

  • MHY1485 New

    MHY1485 is a potent, and cell-permeable mTOR activator, and also potently inhibits autophagy.

  • CHIR-99021 (CT99021) New

    CHIR-99021 (CT99021) is a GSK-3α and GSK-3β inhibitor with IC50 of 10 nM and 6.7 nM, respectively. CHIR99201 does not exhibit cross-reactivity against cyclin-dependent kinases (CDKs) and shows a 350-fold selectivity toward GSK-3β compared to CDKs. CHIR99021 functions as a Wnt/β-catenin activator and induces autophagy.

  • Dorsomorphin (Compound C) New

    Dorsomorphin is a potent, reversible, selective AMPK inhibitor with Ki of 109 nM in cell-free assays, exhibiting no significant inhibition of several structurally related kinases including ZAPK, SYK, PKCθ, PKA, and JAK3. Dorsomorphin selectively inhibits the BMP type I receptors ALK2, ALK3 and ALK6. Dorsomorphin is used in promoting specific cell differentiation and inducing cancer cell line autophagy.

  • Everolimus (RAD001)

    Everolimus (RAD001) is an mTOR inhibitor of FKBP12 with IC50 of 1.6-2.4 nM in a cell-free assay. Everolimus induces cell apoptosis and autophagy and inhibits tumor cells proliferation.

  • AZD8055

    AZD8055 is a novel ATP-competitive mTOR inhibitor with IC50 of 0.8 nM in MDA-MB-468 cells with excellent selectivity (∼1,000-fold) against PI3K isoforms and ATM/DNA-PK. AZD8055 induces caspase-dependent apoptosis and also induces autophagy. Phase 1.

    Features:First drug to inhibit both types of mTOR protein.

  • Torin 1

    Torin 1 is a potent inhibitor of mTORC1/2 with IC50 of 2 nM/10 nM in cell-free assays; exhibits 1000-fold selectivity for mTOR than PI3K.

  • Temsirolimus (CCI-779)

    Temsirolimus (CCI-779, NSC 683864) is a specific mTOR inhibitor with IC50 of 1.76 μM in a cell-free assay. Temsirolimus induces autophagy and apoptosis.

  • Sapanisertib (MLN0128)

    Sapanisertib (MLN0128, INK 128, TAK-228) is a potent and selective mTOR inhibitor with IC50 of 1 nM in cell-free assays; >200-fold less potent to class I PI3K isoforms, superior in blocking mTORC1/2 and sensitive to pro-invasion genes (vs Rapamycin). Phase 1.

  • Tacrolimus (FK506)

    Tacrolimus (FK506, FR900506, Fujimycin, Prograf) is a 23-membered macrolide lactone, it reduces peptidyl-prolyl isomerase activity in T cells by binding to the immunophilin FKBP12 (FK506 binding protein) creating a new complex. Tacrolimus also inhibits the phosphatase activity of calcineurin. Tacrolimus induces vascular endothelial autophagy.

  • KU-0063794

    KU-0063794 is a potent and highly specific dual-mTOR inhibitor of mTORC1 and mTORC2 with IC50 of ~10 nM in cell-free assays; no effect on PI3Ks.

Tags: buy Rapamycin (Sirolimus) | Rapamycin (Sirolimus) supplier | purchase Rapamycin (Sirolimus) | Rapamycin (Sirolimus) cost | Rapamycin (Sirolimus) manufacturer | order Rapamycin (Sirolimus) | Rapamycin (Sirolimus) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID